Using light to control brain activity to treat Alzheimer's disease
Controlling oscillations to treat Alzheimers disease targeting the basal forebrain parvalbuminsystem
['FUNDING_OTHER'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11126910
This study is exploring a new way to help people with Alzheimer's by using light to activate certain brain cells that are important for memory, and it aims to see if this can reduce harmful plaques and improve thinking skills.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11126910 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating Alzheimer's disease by using light to stimulate specific neurons in the brain. The study focuses on the basal forebrain parvalbumin system, aiming to control gamma oscillations that are crucial for memory and cognition. By employing optogenetic techniques in mouse models of Alzheimer's, the researchers will assess the effectiveness of this method in reducing amyloid-beta plaques and improving cognitive function. The research will also explore whether combining this technique with other sensory stimulation methods can enhance treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with early-stage Alzheimer's disease or those at high risk for developing the condition.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that significantly improve cognitive function and quality of life for Alzheimer's patients.
How similar studies have performed: Previous studies have shown promising results using similar optogenetic approaches in animal models, but this specific method has not yet been independently validated in humans.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHIFFINO, FELIPE LOPES — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: SCHIFFINO, FELIPE LOPES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia